Partnership Improves Patient Access to Apealea Outside US

Partnership Improves Patient Access to Apealea Outside US
Elevar Therapeutics and Tanner Pharma Group have partnered to make Apealea (paclitaxel micellar) accessible in areas outside the U.S. where the medication is not available. The companies have created a global named patient program, also known as an early or expanded access program, which provides physicians with a framework to legally and ethically prescribe investigational or approved drugs for patients before they become commercially available. Under the agreement, Tanner will be the exclusive supplier of Apealea in these areas. "We are excited to partner with Tanner to ensure patients outside of the U.S. who have no therapeutic alternatives are able to access to Apealea through a named patient program," Alex Kim, Elevar's CEO, said in a press release. Apealea is an injectable and water-soluble form of paclitaxel, a known chemotherapy used in various solid tumors, including ovarian cancer. Medicines like paclitaxel that enter the bloodstream need to dissolve in water to reach therapeutic concentrations without having to be injected at very high doses. Paclitaxel
Subscribe or to access all post and page content.